Table 2.
Comparison of Changes in Aerobic Fitness, Neurocognition, and Brain-Derived Neurotropic Factor Following Aerobic Exercise or Treatment as Usual
Treatment | Intention to Treat (n = 33) | Study Completers (n = 26) | Cohen’s d b | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Mean Δ | SD | F a | P | Mean Δ | SD | F a | P | |||
Aerobic fitness | Treatment as usual | −0.71 | 2.78 | 3.62 | .001** | −0.48 | 3.07 | 12.24 | .002** | 1.06 |
Aerobic exercise | 3.11 | 3.26 | 3.82 | 3.21 | ||||||
Neurocognition | Treatment as usual | 0.35 | 7.16 | 1.34 | .19 | −1.15 | 5.80 | 5.24 | .031* | 0.93 |
Aerobic exercise | 3.25 | 4.93 | 4.00 | 5.21 | ||||||
BDNF | Treatment as usual | 1.39 | 4.64 | 0.08 | .94 | 0.17 | 3.50 | 0.76 | .46 | 0.30 |
Aerobic exercise | 1.26 | 5.02 | 1.55 | 5.56 |
Note: Aerobic fitness, VO2peak (ml/kg/min); Neurocognition, MATRICS Consensus Cognitive Battery (MCCB) composite score; BDNF, serum BDNF (ng/ml).
aControlling for the impact of sex, age, and changes in antipsychotics, antidepressants and phase of menstrual cycle.
bFor study completers.
*P < .05, **P < .01.